Document is current
Any future updates will be listed below
-
Authors
Wataya, Tomohiro https://orcid.org/0000-0002-1224-6601
Miura, Azusa
Sakisuka, Takahisa
Fujiwara, Masahiro https://orcid.org/0000-0003-3423-7658
Tanaka, Hisashi https://orcid.org/0000-0002-6148-0672
Hiraoka, Yu
Sato, Junya https://orcid.org/0000-0002-1206-2036
Tomiyama, Miyuki
Nishigaki, Daiki https://orcid.org/0000-0002-7006-3408
Kita, Kosuke https://orcid.org/0000-0002-5825-3348
Suzuki, Yuki https://orcid.org/0000-0002-1572-5771
Kido, Shoji https://orcid.org/0000-0001-5293-4110
Tomiyama, Noriyuki https://orcid.org/0000-0001-9918-7327
-
Funding
Funding for this research was provided by:
Kaken Pharmaceutical (21H03840)
Osaka University
- License Information
-
More Information
Article History
Received: 27 March 2024
Accepted: 19 December 2024
First Online: 8 January 2025
Declarations
:
: Yu Hiraoka is the director of GramEye Inc. and owns stock of the company. The other authors declare no conflicts of interest.
: This study was approved by Ethics Review Board of Osaka University Hospital (3/22/2022 #21498).
: Statement that all human and animal studies have been approved and performed in accordance with ethical standards.
: The need for informed consent was waived because of the retrospective nature of this study.
